Abstract
Background and Aims: Background: Nonstatin drugs are often required to achieve LDL cholesterol (LDL-C) goals in patients of homozygous familial hypercholesterolemia(HoFH). PCSK9 inhibitors, evolocumab and alirocumab effectively lower LDL-C. Evolocumab has been approved for use in India. Aims: The objective was to study the efficacy of additional evolocumab in lowering LDL-C and clinical outcomes in patients of HoFH.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
